DC-XLEAR
Today, Xlear is filing a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA is a first step in seeking authorization of Xlear Nasal Spray as a new hygiene tool to help in combat the SARS-CoV-2 virus, the virus that causes COVID-19.
Xlear’s Pre-EUA Request is based on initial data suggesting Xlear Nasal Spray may reduce SARS-CoV-2 viral load in the nose, and otherwise attenuate the virus. “Studies show that regular nasal cleansing may help reduce viral infections, including from the SARS-CoV-2 virus (COVID-19),” said Dr. Gustavo Ferrer, a doctor and global respiratory disease expert who has studied the use of Xlear Nasal Spray to combat SARS-CoV-2. “The concept is straight-forward: Cleansing the nose means less virus, less virus produces less risk of infection,” Dr. Ferrer added.
The Pre-EUA Request is focused on the cleansing uses of Xlear, however it follows on recent studies suggesting Xlear is both antiviral and virucidal against SARS-CoV-2:
- A clinical case study of three “[s]ymptomatic, COVID-19 patients, treated with [Xlear],” found “rapid clinical improvement and shorten[ed] time” to negative PCR tests. https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extract-nasal-spray-solution-in-covid-19-case-series .
- Xylitol, which is one of the Ingredients of Xlear, has been shown to have inhibitory properties versus SARS-CoV-2 in cell culture, in vitro . https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1.full
- Later in vitro studies with Xlear suggested it might provide a “replicable means to deactivate SARS-CoV-2 . . . to an undetectable amount of infectious virus.” https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1.full
The linchpin of FDA’s COVID-19 EUA determinations is a risk-benefit assessment — given the threat of a global pandemic, do the possible benefits of the emergency use, outweigh any known risks. Xlear has been used by millions of people over the last twenty years for cleansing and moisturizing the nasal cavities without a single report of a significant adverse event. At the same time, preliminary data shows Xlear has potential benefits versus SARS-CoV-2. “More research will be needed to confirm the effectiveness of Xlear versus SARS-CoV-2. However, we believe the available data clearly shows potential benefits outweigh any practically non-existent risks, ” said Nate Jones, CEO of Xlear. “We hope to move forward quickly with FDA to address a gap in current hygiene strategies against SARS-CoV-2. People should be using Xlear as part of a layered defense to prevent getting COVID-19. If everyone used Xlear, in addition to taking other steps recommended by public health officials, we believe we could drive SARS-CoV-2 infection rates down nationwide,” Jones added.
Xlear is currently sold in over 50,000 pharmacies, grocery stores, and online as a nasal irrigant for cleansing and moisturizing the nasal cavities.
More information on Xlear: https://xlear.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005492/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pure Lithium and E3 Lithium Report Results From Phase 1 of the Lithium Metal Battery Joint Development Agreement22.5.2025 09:15:00 CEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce initial results from the battery cells manufactured under the Joint Development Agreement with E3 Lithium, using E3 Lithium’s brines and DLE technology and Pure Lithium’s innovative extraction and battery technology. Several variations of E3’s lithium chloride concentrate were used to make lithium metal anodes at Pure Lithium’s Boston facility. The lithium from the E3 concentrated lithium chloride was electrodeposited as pure lithium metal onto a copper substrate, creating a complete, battery ready anode. These anodes were then assembled by Pure Lithium into batteries, and their electrochemical performance was evaluated in full cells. Notable results include: Lithium Metal Purity: The various E3 brine streams all achieved a very high purity level, > 99.9% pure lithium metal as tested by ICP-OES analysis. Cell Performance (Life Cycle): This tests for the number o
Manhattan Associates Unveils Agentic AI Innovation at Momentum 202522.5.2025 09:00:00 CEST | Press release
Kicking off Momentum 2025, Manhattan Associates Inc. (NASDAQ: MANH) today announced sweeping Agentic AI support within Manhattan Active® solutions that includes intelligent, autonomous digital agents to revolutionise supply chain commerce execution, optimisation, and user experiences. These out-of-the-box AI agents, powered by large language models (LLMs) and Manhattan’s cloud-native, all-microservice API architecture, will autonomously perform tasks, adapt to changing conditions, and dynamically orchestrate workflows. This breakthrough marks a generational leap from traditional chatbots and static workflow configurations to dynamic, intelligent, and situationally aware orchestration across the entire supply chain and commerce lifecycle. Among the first groundbreaking AI agents announced are the Intelligent Store Manager, Labor Optimizer Agent, Wave Inventory Research Agent, Contextual Data Assistant, and Virtual Configuration Consultant. These digital agents allow users to interact wi
Empowering Local Industry: SFI Health™ EMEA Commits to South African Packing Operations22.5.2025 08:30:00 CEST | Press release
Local manufacturer will take care of packing company’s key brands to make a difference in the community: Packed with Care, Packed right Here SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is proud to announce that the packing of its branded products in South Africa will be now fully managed locally leveraging local talent and facilities. The company is known for its clinically researched products in microbiome, cognition, and well-being. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250521282786/en/ This initiative enhances SFI Health South Africa’s ability to offer greater flexibility in pack sizes, ensuring a product portfolio that aligns more closely with the needs of South African consumers. By taking this step, the company aims to make its scientifically supported health solutions more accessible, without compromising on quality or efficacy. Simultaneously, this initiative
Lenovo Group: Q4 and Full Year Financial Results 2024/2522.5.2025 06:21:00 CEST | Press release
Lenovo delivers strong full-year performance – innovation and operational excellence further strengthen competitiveness Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today announced Q4 and full year results for the fiscal year 2024/25, reporting significant increases in overall group revenue and profit. For the full year, revenue grew 21% year-on-year to US$69.1 billion, marking the Group’s second-highest annual revenue in its history. Net income was up 36% year-on-year to US$1.4 billion on a non-Hong Kong Financial Reporting Standards (non-HKFRS[1]) basis. The Group’s diversified growth engines continue to accelerate, with non-PC revenue mix up nearly five points year-on-year to 47%. All business groups were healthy and strong and met their strategic intent and financial goals, and all sales geographies gained double-digit revenue growth year-on-year, reflecting the strength of the Group’s diversified businesses and resilient global footpr
Mastercard and OCTO Join Forces to Promote Responsible Driving Through Loyalty Programs21.5.2025 18:10:00 CEST | Press release
Thanks to Mastercard’s SessionM platform, OCTO will offer valuable incentives to more responsible drivers while increasing customer engagement and loyalty to insurance companies. Mastercard and OCTO, a global leader in advanced telematics solutions and data analytics services for the insurance and automotive sectors, today announce a collaboration aimed at redefining the interaction between insurance companies and customers by encouraging safer driving behaviors through an innovative loyalty program. The partnership involves the integration of Mastercard’s SessionM – a platform designed to support businesses in managing customer loyalty and engagement – with OCTO’s patented scoring models, which assess driving behavior using either physical devices (black boxes) or digital solutions (apps). This agreement has a dual objective: for drivers, it provides tangible benefits such as discounts on auto, home, and travel insurance, as well as other rewards, in exchange for safe and responsible
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom